Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026

Single-dose miv-cel reportedly showed clinical benefit in progressive multiple sclerosis, with CAR T-cell penetration into the central nervous system and improved disability scores. The treatment is described as removing the need for chronic immunotherapies; the article provides no trial size, numerical results, or timing.